中国临床药理学与治疗学2011，Vol.16Issue(12)：1414-1418,5.
β1肾上腺素受体与CYP2D6基因多态性对美托洛尔抗高血压治疗的影响
Effectes of β1-adrenergic receptor and CYP2D6 gene polymorphism on metoprolol antihypertension therapy
摘要
Abstract
AIM: To investigate effects of β1-adrenergic receptor and CYP2D6 gene polymorphism on metoprolol antihypertension therapy. METHODS: 120 cases of patients with essential hypertension were detected by β1 -adrenergic receptor and CYP2D6 gene polymorphism, 118 patients with Arg 389 allele in β1- adrenergic re-ceptor gene chosen from 120 essential hypertension patients were divided into three phenotype groups according to CYP2D6 gene mutations: the poor metabolism group(PM, 55 cases), intermediate metabolism group (IM, 36 cases)and extensive metabolism group(EM, 27 cases). The subjects of PM, IM and EM were administratedwith metoprolol for the same doseQOO mg/d), taking orally twice a day. Blood pressures, heart rates and side effects were observed during 4-week following-up. RESULTS: Blood pressure and heart rate in group PM, IM and EM were decreased, especially, obviously decreased in group PM, however, the incidence of side effect was significantly increased in group PM. CONCLUSION: The genetic polymorphism of β1- ad-renergic receptor and CYP2D6 was associated with the efficiency of metoprolol antihyperten-sion therapy.关键词
原发性高血压/β1肾上腺素受体/CYP2D6/基因多态性/美托洛尔Key words
Essential hypertension/β1- adrenergic receptor/CYP2D6/Genetic polymorphism/Metoprolol分类
医药卫生引用本文复制引用
徐承华,杨玉雯,曹蘅..β1肾上腺素受体与CYP2D6基因多态性对美托洛尔抗高血压治疗的影响[J].中国临床药理学与治疗学,2011,16(12):1414-1418,5.基金项目
芜湖市科技计划项目(2008710) （2008710）
